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Background: Regardless of worries over clinical research and various initiatives to overcome problems, few
quantitative data on the numbers and type of clinical research exist. This article aims to describe the volume and
type of clinical research in 2002 and 2007 in Finland.
Methods: The research law in Finland requires all medical research to be submitted to regional ethics committees
(RECs). Data from all new projects in 2002 and 2007 were collected from REC files and the characteristics of clinical
projects (76% of all submissions) were analyzed.
Results: The number of clinical projects was large, but declining: 794 in 2002 and 762 in 2007. Drug research
(mainly trials) represented 29% and 34% of the clinical projects; their total number had not declined, but those
without a commercial sponsor had. The number of different principal investigators was large (630 and 581). Most
projects were observational, while an experimental design was used in 43% of projects. Multi-center studies were
common. In half of the projects, the main funder was health care or was done as unpaid work; 31% had industry
funding as the main source. There was a clear difference in the type of research by sponsorship. Industry-funded
research was largely drug research, international multi-center studies, with randomized controlled or other
experimental design. The findings for the two years were similar, but a university hospital as the main research site
became less common between 2002 and 2007.
Conclusions: Clinical research projects were common, but numbers are declining; research was largely funded by
health care, with many physicians involved. Drug trials were a minority, even though most research promotion
efforts and regulation concerns them.
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Clinical research is a key element in strengthening the
scientific basis of health services. Academic institutions
and researchers in North America, and later, in Europe
have expressed concerns about clinical research, while
various initiatives to overcome those problems have
been undertaken [1-10]. Regardless of these concerns,
clinical research or clinical trials as a research institution
have not been extensively studied. Previously, we have
mapped the situation in one European country, Finland,
using various sources [11]. Our results suggested that* Correspondence: elina.hemminki@thl.fi
1National Institute for Health and Welfare, P.O. Box 30, Helsinki 00271, Finland
2Hjelt Institute/Department of Public Health, University of Helsinki,
P.O. Box 41, Helsinki 00014, Finland
Full list of author information is available at the end of the article
© 2013 Hemminki et al.; licensee BioMed Cen
Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumthe governance and funding of clinical research in Finland
was fragmented.
The aim of this paper is to describe the volume and
orientation of clinical research in the same country by
using submissions made to ethics committees in 2002
and 2007: What kind of clinical research was proposed
to the committees, by whom, who sponsored it and how
did sponsorship relate to the characteristics of research.
The research law in Finland requires that all clinical re-
search has to be considered by either locally based official
research ethics committees (RECs) or a central committee.
That requirement gave us a good opportunity to map the
situation regarding clinical research in the country as a
whole.
Finland is one of the Nordic welfare states, with a large
public sector. A comparison to five European countriestral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Proportions (%) of different type of medical
research projects in Finland in 2002 and 2007; projects
submitted to the official Finnish ethics committees1
2002 2007 Total P value2
(n) (1014) (1046) (2060)
Drug research 22.9 24.9 24.0 0.287
Other medical research3 64.7 57.3 60.9 0.001
Non-medical research3 11.7 16.7 14.3 0.001
Missing 0.7 1.1 0.8
Total 100 100 100
Clinical research 78.3 72.8 75.5 0.01
(n) (794) (762) (1556)
1Includes projects handled by the Central committee.
2Comparison of the two years (t-test); in calculation P values, projects with
missing information were ignored.
3As defined in the research law (see Methods).
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general were high in Finland, but much of that was due
to R&D undertaken by corporations [11]. Connections
between public and private research units were more
common in Finland than in the comparison countries
(Denmark, Ireland, the Netherlands, Norway and
Switzerland) [12]. The Finnish health care is largely public
and decentralized, guided by local politicians. The state
regulates health care through laws and steering, with state
subsidies, and retrospective control. Health service fund-
ing involves two intertwined systems: first, a community
based, tax-funded area-based system covering most in-
patient care and much of out-patient care, and secondly, a
national health insurance covering part of private care, oc-
cupational care, drugs, travel, and sickness absence costs.
Methods
The research law requires that all medical research has
to be submitted to an official REC. The RECs are area-
based and the handling REC is determined by the work
place of the principal investigator (PI). All multinational
drug trials have to be submitted first to the central com-
mittee, but it delegates most of these to the official
RECs. Practically all clinical research is included in the
definition of medical research. Before 2011 the ethics re-
view system for non-medical research in Finland was
voluntary and unsystematic, and the official RECs had
also handled other types of research, such as nursing or
psychological research, usually at the request of re-
searchers or the research site.
All projects submitted for the first time in 2002 and
2007 to one of the 20 official RECs and their subcommit-
tees in continental Finland or to the central committee,
were analyzed. The years 2002 and 2007 were chosen as
we will also be studying publication bias and wanted to
have at least five years to follow-up on appearance of pub-
lications (until 2012).
For each project, standard data for describing it and
how it was handled were collected by researchers from
REC documents. Filing of project submissions varied by
REC and REC-secretaries helped to locate the needed
documents. Usually meeting notes and summary data
from the original submissions were available; the full ap-
plication was not usually available. These were either in
paper or electronic format. Most data were collected on
site, but some smaller RECs sent copies of the documents.
Data were extracted in written form or coded by the data
collector. Data were entered into an electronic form
(PASW Statistics 18). Data included the professional char-
acteristics of PIs, research sites, field of research, sponsor,
research methodology, REC decision, and handling fee.
It was possible for a single project to have several sub-
missions (those not decided on at the first submission and
those having later amendments). Data were collected fromeach submission and later combined per project by identi-
fying the same project by the title, and if needed the PI
and the ethics committee code. In the analysis each pro-
ject was counted only once.
Collected data were coded either on site or later using
all available information (Appendix 1). The main funder
was as given in the application to the REC and was
coded during data collection into the categories: indus-
try, non-commercial (public) fund, or health care. Health
care funding includes state subsidies to hospitals to do
research, work done within normal working hours, and
unpaid work.
We first calculated what proportion of all projects
were clinical research projects, and then analyzed the clin-
ical projects only. Clinical research projects (called clinical
projects in brief) were defined based on two variables
(“Type of research” and “Main content”) categorized at
the time of data collection using all available information
(see Appendix 1 for details).Permissions and ethics
The whole project (MERGO Ethical review and adminis-
trative governance of clinical research) received a positive
statement from the National Institute for Health and Wel-
fare’s ethics committee (June 17, 2010, amendment Jan 27,
2011). To study the submissions of research projects to
the RECs in 2002 and 2007, special permission was
obtained from the Health Ministry (STM/4257/2008) with
later additions for new researchers; the confidentiality re-
quirements of the Health Ministry were followed.Results
In 2002 and 2007 the official RECs received 2,060 sub-
missions for research projects (Table 1). Three-quarters
of the projects were defined as clinical projects. The
subsequent information concerns only these.
Table 2 Description of clinical research projects in
Finland in 2002 and 2007, proportions (%) of projects1
2002 2007 Total P value6
(n) 794 762 1556
Type
Domestic drug research 11.1 13.6 12.4 0.601
International drug research 18.1 20.4 19.2 0.615
Other medical research 70.8 66.0 68.4 0.090
Main content
Treatment 54.0 56.6 55.3 0.443
Diagnostics and disease 24.0 18.0 21.1 0.192
Biomedical 8.7 5.6 7.2 0.545
Prevention 7.2 5.0 6.1 0.665
Other + missing 6.1 14.8 10.3 –
Approach
Randomized controlled trial 15.9 23.8 19.8 0.092
Trial + intervention 24.3 21.1 22.7 0.475
Observational 43.7 41.5 42.6 0.567
Documents + registers 4.8 6.2 5.5 0.780
Other + missing 11.3 7.4 9.4 –
Main funder2
Industry 28.7 33.7 31.2 0.236
Public fund 16.3 16.0 16.1 0.966
Health care 52.1 42.3 47.3 0.010
Missing 2.9 8.0 5.4 –
Data collection site3
University hospital 63.8 43.7 54.0 <0.001
Other public health care facility 13.5 20.1 16.7 0.165
Private care 7.5 7.4 7.4 0.984
Other place 10.9 14.7 12.8 0.417
Missing 4.3 14.1 9.1 –
Total 100 100 100
Non-commercial4 75.4 70.9 73.2 0.087
Multi-center study5
National 27.8 30.7 29.2 0.497
International 21.3 23.8 22.5 0.576
1For the explanations of the categories, see Appendix 1.
2As given in the application. Health care includes state subsidy to hospitals to
do research, work done within normal working hours or on own time.
3In multi-center studies, the place of the principal investigator was chosen for
the main research site.
4Administratively non-commercial i.e. exempted from REC fee.
5A project can be both national and international multicenter project.
6Comparison of the two years (t-test); in calculation P values, projects with
missing information were ignored.
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varied notably, from 1 to 291 in 2002 and from 1 to 321
in 2007. Most clinical projects were handled by the five
university hospital RECs, and only the central committee
non-university hospital REC handled more than 15 pro-
jects per year.
The number of different PIs was 630 in 2002 (794 pro-
jects) and 581 in 2007 (762 projects) in 2007. Thus one
PI could have submitted multiple clinical projects in one
year and that occurred more often in 2007 compared to
2002. The maximum number of projects per PI was 8 in
2002 and 9 in 2007.
Even though the total number of research projects did
not decline (Table 1), the number of clinical projects
showed a small decline between 2002 and 2007 (Table 2).
The number of drug research projects (mainly trials) did
not decline (232 in 2002 and 259 in 2007), but there was
a decline in other medical research projects. Drug re-
search represented 29% and 34% of the clinical projects
in the respective years (Table 2). More than half of the
drug research projects were international (Table 2). Over
half (55%) of the clinical projects dealt with treatment
and 21% were classified as diagnostic projects or studied
disease characteristics.
The proportions of different types of clinical projects
in the two years were relatively similar, but there were
more clinical projects in 2007 that could not be classi-
fied on the basis of the information in the documents. If
those were excluded from the denominator, the propor-
tions of treatment projects somewhat increased (from
58% to 66%, P ≤0.01) and diagnostic/disease somewhat
declined (26% and 21%, P = 0.07).
The most common approach used was observational,
in which patients or research subjects were studied with-
out exposing them to research interventions (Table 2).
We classified 43% as experimental (trials) having either
a comparable or non-comparable control group or with-
out an explicit control group. The share of randomized
controlled trials (RCTs) somewhat increased between
2002 and 2007 (from 16% to 24%) even though this was
not statistically significant (Table 2).
The most common data collection site (in multi-center
studies the place where the Finnish PI collected the data)
was a university hospital, but this was less so in 2007
(Table 2). Other public health care facilities, particularly
central hospitals other than university hospitals, had more
projects in 2007. However, in 2007 the information on the
data collection site was lacking for more projects than in
2002, making the comparison potentially unreliable.
Usually the main data collection site was also the work
place of the PI (as given in the application), but not al-
ways. Finnish physicians can work in both public and
private care at the same time. We cross-tabulated the
data on the collection site and the work place of the PI.Out of 849 projects in which the work-place of PI was de-
fined as a university central hospital, in 14% the main data
collection site was elsewhere, particularly in other central
hospitals (7.3%); 1.2% were in private care. Out of 238 pro-
jects in which the work-place of the PI was defined as
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the projects the main data collection site was elsewhere,
most commonly (25%) in a university hospital.
In both years domestic and international multi-center
studies were common (Table 2). Overall, 35% in 2002
and 39% in 2007 were multicenter studies. We did not
collect systematic information on what kinds of institu-
tions participated in multi-center studies as partners.
The most common main funder was “health care”
(Table 2), which meant that research was mainly paid for
by health care, including through state subsidies to hos-
pitals, work done within normal working hours, or un-
funded research (done on own time). In about a third of
the projects the main funder was industry. However, the
documents specified clearly only the main funder, and
very likely many projects were funded from several
sources. The proportions in the two years were relatively
similar, but there were more projects in 2007 that could
not be classified on the basis of the information in the
documents used (Table 2).
Administratively, non-commercial projects were de-
fined on the basis of whether the research ethics com-
mittee (REC) had exempted the study from the handling
fee. In 2002, 75% and in 2007, 71% of the projects were
exempted (Table 2). Practically all projects funded by a
public fund or health care were exempted, but also 21%
of industry funded projects in 2002 and 16% in 2007
were exempted (Table 3). It is likely that these were pro-
jects that received some funding from industry (e.g., do-
nations of drugs or medical devices), but which were not
fully covered by industry.
Table 3 describes the characteristics of the clinical pro-
jects by the main funder. There was a clear difference in
the type of research by sponsorship. Industry funded re-
search was largely drug research and concerned treat-
ment, with most being RCTs or other types of
experimental designs. Publicly funded and health-care-
funded research was rarely drug research and very few
were RCTs, but some had other experimental designs;
the most common approach was patient follow-up (ob-
servational studies). The main content was more varied
than in industry funded research, particularly in projects
funded by public grants. Health-care-funded projects
were most commonly treatment and diagnostic/disease
projects.
Of the 232 drug research projects in 2002 and 259
projects in 2007, 79% and 83%, respectively, were funded
by industry. Most industry funded research was multi-
center studies, usually international (i.e., including cen-
ters outside Finland). Also, projects with public funding
were frequently multi-center studies, though more often
domestic. Health-care-funded research was less fre-
quently multi-center, and when it was, it was mainly do-
mestic to Finland.Results for the two years were similar with regards to
type, main content, multicenter and non-commercial
status. With regards to approach and the data collection
site, results differed across the two study years. Drug tri-
als sponsored by industry somewhat increased between
2002 (n = 180) and 2007 (n = 214), but those without a
commercial sponsor did not (n = 47 and 41). In industry
sponsored projects, RCTs became more common between
2002 and 2007, but not in other projects (Table 3).
In 2002 the main data collection site was a university
hospital in all types of research, but that had changed by
2007. In 2007, 39% of industry sponsored projects were
conducted in university hospitals; projects in other pub-
lic health care facilities had become more common
(Table 3). The share of projects conducted in private
health care settings (16% and 18%) remained the same.
University hospitals had also become less common study
sites for public grant and health-care-funded projects,
even though among health-care-funded projects they
were still the most common site (53%). If projects that
lacked information on the study site are ignored, 75% of
health-care-funded projects were conducted in univer-
sity hospitals in 2002 and 59% in 2007 (P <0.001).
Discussion
The number of clinical research projects submitted to
the Finnish research ethics committees in the two sam-
pled years was high, but declined between 2002 and
2007, even though the total number of medical research
projects did not. Most clinical research projects were
studies on treatments, diagnosis, or disease mechanisms,
and about half were observational. Most projects were
non-commercial. Thirty-two percent of the clinical pro-
jects concerned drugs and their numbers did not decline
during the study period. The number of drug projects
with commercial sponsorship increased somewhat, but
those without a commercial sponsor did not. The num-
ber of different PIs was high. Most projects were health
care funded or done as unpaid work. University hospitals
were the most common research sites, but declined be-
tween 2002 and 2007, particularly for industry funded
research. Those funded by industry differed from the rest
of the projects in terms of all the studied characteristics,
while also being concentrated on drug trials. Industry
sponsored projects were often RCTs. The results by spon-
sor in the two studied years were mostly similar, but some
differences by the funder became larger over time.
Comments on findings
We found little comparable data from other countries.
In the Netherlands, national statistics from accredited
ethics committees on medical research have been pub-
lished in English for 2010 [13]. In addition, we comment
on the findings and compare our results, where feasible,
Table 3 Relation of the characteristics of clinical research projects to funding, projects submitted to the official Finnish
ethics committees in 2002 and 2007, %1
(n) 2002 2007
Industry Public Health care4 P value6 Industry Public Health care4 P value6
(228) (129) (414) (257) (122) (322)
Type
Domestic drug research 20.2 6.2 7.5 <0.001 25.7 6.6 8.1 <0.001
International drug research 58.8 1.6 1.4 <0.001 57.6 4.1 0.6 <0.001
Other medical research 21.1 92.2 91.1 <0.001 16.7 89.3 91.3 <0.001
Main content
Treatment 80.3 23.2 48.3 <0.001 87.5 33.6 46.0 <0.001
Diagnostics and disease2 4.8 31.8 33.6 <0.001 2.7 23.8 28.8 <0.001
Biomedical3 7.0 23.3 5.6 0.478 3.1 16.4 4.7 0.328
Prevention 6.1 15.5 5.3 0.673 2.7 13.1 4.7 0.212
Other + missing 1.8 6.2 7.2 3.9 13.1 15.8
Approach
RCT 43.0 7.8 3.9 <0.001 59.9 6.6 4.3 <0.001
Trial + intervention 36.0 14.7 20.0 <0.001 28.8 20.5 16.2 <0.001
Observational 16.2 59.6 54.1 <0.001 5.8 56.6 61.5 <0.001
Documents + registers 1.3 3.1 7.6 <0.001 2.7 5.7 8.4 0.004
Other + missing 3.5 14.8 14.4 2.8 10.6 9.6
Data collection site2
University hospital 57.0 56.6 72.5 <0.001 38.5 38.5 53.4 <0.001
Other public health care facility 9.6 16.4 15.5 0.486 16.7 18.9 26.7 0.760
Private care 16.3 3.8 2.4 <0.001 17.9 3.3 1.7 <0.001
Other place 14.0 21.6 6.2 <0.001 19.9 22.1 9.2 <0.001
Missing 3.1 1.6 3.4 7.0 17.2 9.0
Total 100 100 100 100 100 100
Non-commercial3 20.6 96.1 98.8 <0.001 15.6 98.4 99.1 <0.001
Multi-center study5
National 46.1 34.9 16.4 <0.001 46.7 33.6 22.0 <0.001
International 61.0 9.3 3.6 <0.001 59.1 12.3 3.1 <0.001
1For the explanations of the categories, see Appendix 1.
2In multi-center studies, the place of the principal investigator was chosen for the main research site.
3Administratively non-commercial i.e. exempted from REC fee.
4Health care includes state subsidy to hospitals to do research, work done within normal working hours or on own time.
5A project can be both national and international multicenter project.
6Comparison of industry funded projects to health care funded projects (t-test); in calculation P values, projects with missing information were ignored.
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the US studies came from a trial register (clinicaltrials.
com), and they do not refer to a defined period of time
(accumulation of studies started in 2000s) or place (several
countries are partly covered) and are thus not strictly
comparable.
The number of clinical research projects in the sam-
pled years was high, but declining. In our previous study
[11] we reported data from national statistics, conclud-
ing that the quality and quantity of Finnish clinical re-
search had been high compared to some other countries,
but volume had declined in the 2000s [15]. One possiblefactor that reduced the number of clinical projects is the
European Clinical Trials Directive, which came into force
in 2004 in Finland [16]. Another reason may be the tighter
budgeting and oversight of clinical research in health care
units, which has made the real costs visible as well as re-
ducing the number of poorly planned projects. However,
we did not have data on the quality of the projects and do
not know whether the share of poorly planned studies has
declined.
The characteristics of clinical projects in the two stud-
ied years were relatively similar, as one might expect
with a 5-year time difference. However, some findings
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number of clinical projects sponsored by industry had
not declined, but those funded by health care had. Ac-
cordingly, commercial drug research did not decline. In-
dustry funded projects differed from the rest in all
aspects that were examined. RCTs became more com-
mon between 2002 and 2007 in industry sponsored pro-
jects, but not in others. University hospitals served as
the main research site less often. These changes may re-
flect declining state subsidies for clinical research in
health care [16], in addition to increased work pressure
for clinicians in public hospitals.
Finnish regulations require that in the case of medical
studies, each study site has to have a responsible re-
searcher with a medical education. During the study
years the number of different PIs was large and a large
number of the projects were multi-center studies that
also involved other researchers. However, the number of
different PIs declined between 2002 and 2007, and the
number of projects per single PI increased. In a 2006
survey, a high proportion of physicians reported engage-
ment in research (clinical research was not specified),
but later surveys suggested that in many hospitals and
health centers, the possibilities to undertake clinical re-
search were deteriorating, particularly due to the burden
of routine patient care and a lack of time [11].
Data were not available on whether researchers were
continuously engaged in research over time. A study on
clinical trials from the US [1] showed a high turnover of
clinical investigators. In 2007, 26,000 investigators were
registered with the FDA for drug trials, with most of
them registered only for a single trial; foreign investiga-
tors have been replacing domestic ones [1].
According to our summary data, the PI was most com-
monly from a university hospital. However, this may not
reflect the actual circumstances. The recording system of
RECs very likely inflates the importance of university hos-
pitals due to the tradition of local decision-makers allocat-
ing government subsidy money to favor established
researchers from university hospitals as PIs instead of
other co-researchers. Second, projects in the medical
schools and their biotechnology units and the projects
may have been anchored to the hospital rather than the
university in order to be eligible for EVO-funding. Third,
many university hospital physicians have sideline work in
the private sector and the actual study may have been
done there. The web of public, semipublic and private
units has expanded rapidly, and the information demands
in clinical research regulation have not followed this
development.
In about half of the projects the main funder was
“health care”, which indicates a mixture of funding. Mu-
nicipalities allowed health professionals to use their
working hours for clinical research, but they did notdirectly fund clinical research [11]. The work time com-
pensation could be an important support for encour-
aging research, but in practice it is rather limited as the
health professionals’ work-load often prevents research
during working hours. The national health insurance
(KELA) has research funds, but their focus has not been
on clinical research [11].
We did not have data on project size and costs, so
small projects weighed as much as large projects in our
data. Cost data are very difficult to find, as budgeting for
and reporting on research expenses is different for dif-
ferent sponsors, and varies by the type of institute. The
documents only identified clearly the main funder, and it
is possible that external money was more frequently des-
ignated as the main funding source. This makes the con-
tribution of the public sector appear smaller than it is,
as much of their contribution has been in work time and
the creation of infrastructure. On the other hand, anec-
dotal evidence suggests that in commercial projects the
amount of visible money (separately in accounts books)
is relatively larger than the number of projects. It may
be that government and municipality funding has been
used to create the infrastructure for clinical research,
but external funding determines more what types of pro-
jects are undertaken; this increases the role of industry
in directing research.
In the Netherlands [13], RECs handled 702 submis-
sions for medical research in 2010. However, we could
not extract the clinical research or change the submis-
sions into projects to correspond our study, which is a
drawback in the subsequent comparisons. Unlike Finland,
most (58%) of the submissions concerned trials, i.e., re-
search with an experimental design. The proportion of
multicenter studies (38%) was similar to that in Finland.
Like in Finland, about a third concerned drugs, but the
share (47%) sponsored by non-industry sources was higher
than in Finland, where the proportion of drug projects
funded by non-industry sponsors was 16% in 2007. In the
Netherlands, 42% of drug projects were either phase I or
phase II drug trials.
In the American study using trial registration data for
trials initiated in the 2000s, it was found that most trials
concerned drugs (59%) and half of them concerned can-
cer [1]. A later study using the same registration data-
base found that, similar to our study, most trials in
terms of numbers were sponsored by academic health
centers and were small [13]. However, when the number
of patients was studied, most were from industry spon-
sored phase 3 and 4 studies. Likewise in the earlier US
study [1], two-thirds (63%) concerned drugs.
Drug trials
We found that about a third of the clinical projects con-
cerned drugs and overall their numbers had not declined.
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declined somewhat. This is in accordance with the statis-
tics of the drug authority: the total number of started clin-
ical drug trials the years 2001 and 2006 fluctuated
between 238 and 293 declining to 209 trials in 2010, with
the largest decline in phase 2 and phase 1 trials [17]. There
was a decline in the number of trials without an outside
commercial sponsor (academic projects): about 90 in 2002
and 40 in 2010 [17].
A study comparing six European countries found a
notable variation in the trends of the total number of
drug trials and academic drug trials from 2001 to 2009
[18]. For example, the total number of drug trials in-
creased in Italy and in Spain; in Italy due to academic
trials and in Spain due to commercial trials. In UK, there
was a sharp decline in the number of academic trials.
Clinical projects funded by industry have concentrated
on drug trials. This is not unexpected, but raises the ques-
tion of data balance [19-22]. Light et al. [23] claim that
clinical trials in North-America have become a high-profit
sub-industry, largely carried out by for-profit contract re-
search organizations (on behalf of the industry).
In our study years the majority of clinical research
projects were not related to drug research, even though
regulation is centered on drug research [11]. Similarly,
outside Finland there has been a special focus on drug
trials due to the drug industry’s commercial interests
and lobbying power, and in a European context, also due
to the EU mandate. It has been said that the European
Clinical Trials Directive (in force since 2004) makes drug
trials more difficult to undertake and has specifically de-
creased the number of trials sponsored by non-
commercial actors [16,24-26]. Hope for reducing these
problems has now been put in modification of the Clin-
ical Trials Directive, which is currently (Spring 2013)
under discussion (Piret et al., unpublished manuscript).
Methodological comments
The data from each project at our disposal were limited
and for some variables more information was lacking in
2007. Our classification of clinical research as a sub-
class of medical research was subjective. Various defini-
tions and terms have been used for clinical research and
there has been no uniform definition that can be ap-
plied. One could argue that patient-oriented research by
paramedical researchers such as psychologists, which we
excluded, could be defined as clinical research. However,
most projects were easy and clear to classify as clinical
research, and we can confidently consider the data to be
representative of clinical research with proposed start
dates in 2002 and 2007 in Finland.
We also undertook a number of other classifications
(see Appendix 1). Mostly coding was easy and clear cut,
but the complexity of each project was difficult tocompress into the simplified codes we used. For example,
many projects received funding or other resources from
different sources, but only one, apparently the main one,
was indicted in the summary data. More detailed coding
was not considered useful, as for most projects the data
we had at hand were limited.
A strength of our study is that it covers a defined time
period and the entire country. This was due to the med-
ical research law requiring all medical research (includ-
ing clinical research) to be handled in official research
ethics committees. We needed special permission to ac-
cess the data that are currently considered confidential.
The permissions and practices were cumbersome and
took a significant amount of time. The data available in
research ethics committees were useful to us and could
also be for others interested in research policy and out-
comes. To facilitate such research, a change in attitudes
and interpretation of what is public and what is confi-
dential would be welcome.
Appendix 1
Classifications and coding made.
Type (Medical research): In the data collection phase
each project was classified into four groups (domestic
drug research, international drug research, medical re-
search, other research) by the help of the information in
the (summary) study plan and the classification used by
the REC. Medical research is defined by the law: “Med-
ical research means research involving intervention in
the integrity of a person, human embryo or human
foetus for the purpose of increasing knowledge of health,
the causes, symptoms, diagnosis, treatment and preven-
tion of diseases or the nature of diseases in general.”
However, RECs might have adapted that definition in
their classification.
Content (Type of research): The type of research had
14 categories, which were defined at the time of data
collection using all available information. The categories
were combined for this paper into: Treatment (6 patient
treatments), diagnostics and disease (3 disease classes, 8
diagnostics), biomedical (9 biomedical research), preven-
tion (1 prevention, 2 epidemiology), other (4 dentistry, 5
health behavior, 7 health services, 10 psychology, behav-
ioral and social sciences, nutrition, etc., 11 technology,
12 other, 13 nursing studies, 14 sport medicine). Bio-
medical research covers projects in pharmacology,
microbiology, biochemistry, etc. using human samples to
understand physiological and pathological mechanisms
and not focusing on patient outcomes.
Clinical research: Clinical projects were defined by
cross-tabulating variables “Type” and “Content”. Under
“Type” classes, “drug research” and “other medical re-
search” were picked, excluding “other research” and miss-
ing. “Other medical research” was then cross-tabulated by
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were defined as epidemiology, health behavior or psych-
ology were excluded.
The categories of clinical research were combined for
this paper into: Treatment (6 patient treatments), diagnos-
tics and disease (3 disease class, 8 diagnostics), biomedical
(9 biomedical research), prevention (1 prevention, 2 epi-
demiology), other (including 4 dentistry, 5 sport medicine,
health services research).
Approach: Each project was coded afterwards into
nine categories using the project title, method of re-
search, type of research and EudraCT code (yes or no),
and other information in the original data collection file.
The categories were combined for this paper into: RCT,
other trial and intervention (includes 2 other trial, 3
intervention, i.e., having an experimental design), obser-
vational (4 clinical follow-up study, 5 non-clinical
follow-up, 6 not clear), documents and registers (7 a
study based on ready documents only; includes follow-
up studies of trials using documents only), and other (8
other; includes quality assurance).
Principal investigator: The responsible researcher in
Finland, as in REC application.
Work place: of the principal investigator, as in REC
application. The coding was made as for “Data collection
site”.
Data collection site: The site was coded from the
written name of the places where the research was to be
made. If the name was not known to the coder, Google
search was used to get further information. The follow-
ing classes were used: 1 university hospital, 2 other cen-
tral hospital, 3 district hospital, 4 other public hospital, 5
private hospital, 6 private outpatient clinic, 7 public
health center, 8 occupational health, 9 non-profit, pri-
vate, 10 university or research center, 11 polytechnic, 12
industry, private research center, 13 other. Classes 2–4
and 7 were combined to other public health care facility;
5 + 6 + 8 + 9 were combined to (other) private care, 10–13
to other place; there were very few projects in option 8.
In multi-center studies, the place of the principal inves-
tigator was chosen for the main data collection site. In
case of lacking information, the work place of the principle
investigator was used, if it was available (5% of projects).
Domestic multi-center study: At least two study sites
in Finland.
International multi-center study: At least one study
site was abroad.
Main funder: Main funder as given in the application
to REC, coded during data collection into: industry,
non-commercial (public) fund, health care. Health care
includes state subsidy to hospitals to do research, work
done within normal working hours, and as unpaid work.
Non-commercial project: the projected is exempted
from REC fee.Abbreviations
PI: Principal investigator; RCT: Randomized clinical trial; REC: research ethics
committee.
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